Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00162500
Status:
WITHDRAWN
Last Update Posted:
2010-11-10
First Post:
2005-09-11
Brief Title:
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Sponsor:
Hadassah Medical Organization
Organization:
Hadassah Medical Organization
Study Overview
Official Title:
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
Status:
WITHDRAWN
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Rationale
ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4 and CD8 T lymphocytes and therefore could potentially be more effective in the majority of the target population
Purpose
The purpose of this study is to evaluate the safety and initial efficacy of ImMucin a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen TAA
ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4 and CD8 T lymphocytes and therefore could potentially be more effective in the majority of the target population
Purpose
The purpose of this study is to evaluate the safety and initial efficacy of ImMucin a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen TAA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None